Literature DB >> 31710795

Subtypes of COPD Have Unique Distributions and Differential Risk of Mortality.

Kendra A Young1, Elizabeth A Regan2, MeiLan K Han3, Sharon M Lutz4, Margaret Ragland1, Peter J Castaldi5, George R Washko5, Michael H Cho5, Mathew Strand6, Douglas Curran-Everett6, Terri H Beaty7, Russell P Bowler2, Emily S Wan4,8, David A Lynch9, Barry J Make2, Edwin K Silverman5, James D Crapo2, John E Hokanson1, Gregory L Kinney1.   

Abstract

BACKGROUND: Previous attempts to explore the heterogeneity of chronic obstructive pulmonary disease (COPD) clustered individual patients using clinical, demographic, and disease features. We developed continuous multidimensional disease axes based on radiographic and spirometric variables that split into an airway-predominant axis and an emphysema-predominant axis.
METHODS: The COPD Genetic Epidemiology study (COPDGene®) is a cohort of current and former smokers, > 45 years, with at least 10 pack years of smoking history. Spirometry measures, blood pressure and body mass were directly measured. Mortality was assessed through continuing longitudinal follow-up and cause of death was adjudicated. Among 8157 COPDGene® participants with complete spirometry and computed tomography (CT) measures, the top 2 deciles of the airway-predominant and emphysema-predominant axes previously identified were used to categorize individuals into 3 groups having the highest risk for mortality using Cox proportional hazard ratios. These groups were also assessed for causal mortality. Biomarkers of COPD (fibrinogen, soluble receptor for advanced glycation end products [sRAGE], C-reactive protein [CRP], clara cell secretory protein [CC16], surfactant-D [SP-D]) were compared by group.
FINDINGS: High-risk subtype classification was defined for 2638 COPDGene® participants who were in the highest 2 deciles of either the airway-predominant and/or emphysema-predominant axis (32% of the cohort). These high-risk participants fell into 3 groups: airway-predominant disease only (APD-only), emphysema-predominant disease only (EPD-only) and combined APD-EPD. There was 26% mortality for the APD-only group, 21% mortality for the EPD-only group, and 54% mortality for the combined APD-EPD group. The APD-only group (n=1007) was younger, had a lower forced expiratory volume in 1 second (FEV1) percent (%) predicted and a strong association with the preserved ratio-impaired spirometry (PRISm) quadrant. The EPD-only group (n=1006) showed a relatively higher FEV1 % predicted and included largely GOLD stage 0, 1 and 2 partipants. Individuals in each of the 3 high-risk groups were at greater risk for respiratory mortality, while those in the APD-only group were additionally at greater risk for cardiovascular mortality. Biomarker analysis demonstrated a significant association of the APD-only group with CRP, and sRAGE demonstrated greatest significance with both the EPD-only and the combined APD-EPD groups.
INTERPRETATION: Among current and former smokers, individuals in the highest 2 deciles for mortality risk on the airway-predominant axis and the emphysema-predominant axis have unique associations to spirometric patterns, different imaging characteristics, biomarkers and causal mortality. JCOPDF
© 2019.

Entities:  

Keywords:  COPD Genetic Epidemiology; COPDGene; PRISm; airway-predominant disease; biomarkers; chronic obstructive pulmonary disease; copd; emphysema-predominant disease; mortality; preserved ratio-impaired spirometry; subtypes

Year:  2019        PMID: 31710795      PMCID: PMC7020845          DOI: 10.15326/jcopdf.6.5.2019.0150

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  25 in total

1.  Subtypes of patients experiencing exacerbations of COPD and associations with outcomes.

Authors:  Inmaculada Arostegui; Cristobal Esteban; Susana García-Gutierrez; Marisa Bare; Nerea Fernández-de-Larrea; Eduardo Briones; José M Quintana
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

Review 2.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary.

Authors:  R A Pauwels; A S Buist; P Ma; C R Jenkins; S S Hurd
Journal:  Respir Care       Date:  2001-08       Impact factor: 2.258

Review 3.  Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease.

Authors:  Alvar Agustí; James C Hogg
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

4.  Pulmonary emphysema subtypes on computed tomography: the MESA COPD study.

Authors:  Benjamin M Smith; John H M Austin; John D Newell; Belinda M D'Souza; Anna Rozenshtein; Eric A Hoffman; Firas Ahmed; R Graham Barr
Journal:  Am J Med       Date:  2013-10-09       Impact factor: 4.965

5.  CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society.

Authors:  David A Lynch; John H M Austin; James C Hogg; Philippe A Grenier; Hans-Ulrich Kauczor; Alexander A Bankier; R Graham Barr; Thomas V Colby; Jeffrey R Galvin; Pierre Alain Gevenois; Harvey O Coxson; Eric A Hoffman; John D Newell; Massimo Pistolesi; Edwin K Silverman; James D Crapo
Journal:  Radiology       Date:  2015-05-11       Impact factor: 11.105

Review 6.  Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: insights, disappointments and promise.

Authors:  David M Mannino
Journal:  Curr Opin Pulm Med       Date:  2019-03       Impact factor: 3.155

7.  Automated telecommunication to obtain longitudinal follow-up in a multicenter cross-sectional COPD study.

Authors:  Jeffrey I Stewart; Sarah Moyle; Gerard J Criner; Carla Wilson; Ron Tanner; Russell P Bowler; James D Crapo; Robert K Zeldin; Barry J Make; Elizabeth A Regan
Journal:  COPD       Date:  2012-06-07       Impact factor: 2.409

8.  The risk of death by age, sex, and smoking status in the United States: putting health risks in context.

Authors:  Steven Woloshin; Lisa M Schwartz; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

9.  Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study.

Authors:  Emily S Wan; Spyridon Fortis; Elizabeth A Regan; John Hokanson; MeiLan K Han; Richard Casaburi; Barry J Make; James D Crapo; Dawn L DeMeo; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2018-12-01       Impact factor: 30.528

10.  Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene.

Authors:  Emily S Wan; Peter J Castaldi; Michael H Cho; John E Hokanson; Elizabeth A Regan; Barry J Make; Terri H Beaty; MeiLan K Han; Jeffrey L Curtis; Douglas Curran-Everett; David A Lynch; Dawn L DeMeo; James D Crapo; Edwin K Silverman
Journal:  Respir Res       Date:  2014-08-06
View more
  10 in total

1.  The Pressing Need to Redefine "COPD".

Authors:  Peter J Barnes; Jørgen Vestbo; Peter M Calverley
Journal:  Chronic Obstr Pulm Dis       Date:  2019-11

2.  Letter to the Editor: Response by Authors.

Authors:  Katherine E Lowe; John E Hokanson; Barry J Make; Katherine A Pratte; Elizabeth A Regan; Edwin K Silverman; Kendra A Young; Gregory L Kinney; James D Crapo
Journal:  Chronic Obstr Pulm Dis       Date:  2020-04

3.  Journal Club-COPD2020 Update. Global Initiative for Chronic Obstructive Lung Disease 2020 Report and the Journal of the COPD Foundation Special Edition, Moving to a New Definition for COPD: "COPDGene® 2019".

Authors:  Ron Balkissoon
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

4.  Value of Cardiopulmonary Exercise Testing in the Prognosis Assessment of Chronic Obstructive Pulmonary Disease Patients: A Retrospective, Multicentre Cohort Study.

Authors:  Ralf Ewert; Anne Obst; Andreas Mühle; Michael Halank; Jörg Winkler; Bernd Trümper; Gerhard Hoheisel; Andreas Hoheisel; Mark Wiersbitzky; Alexander Heine; Alexander Maiwald; Sven Gläser; Beate Stubbe
Journal:  Respiration       Date:  2021-11-19       Impact factor: 3.966

5.  The Relation Between Clinical Phenotypes, GOLD Groups/Stages and Mortality in COPD Patients - A Prospective Multicenter Study.

Authors:  Kristian Brat; Michal Svoboda; Jaromir Zatloukal; Marek Plutinsky; Eva Volakova; Patrice Popelkova; Barbora Novotna; Tomas Dvorak; Vladimir Koblizek
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-04-28

6.  Diagnostic efficacy of visual subtypes and low attenuation area based on HRCT in the diagnosis of COPD.

Authors:  Dan Zhu; Chen Qiao; Huiling Dai; Yunqian Hu; Qian Xi
Journal:  BMC Pulm Med       Date:  2022-03-06       Impact factor: 3.317

7.  Pulmonary Subtypes Exhibit Differential Global Initiative for Chronic Obstructive Lung Disease Spirometry Stage Progression: The COPDGene® Study.

Authors:  Kendra A Young; Matthew Strand; Margaret F Ragland; Gregory L Kinney; Erin E Austin; Elizabeth A Regan; Katherine E Lowe; Barry J Make; Edwin K Silverman; James D Crapo; John E Hokanson
Journal:  Chronic Obstr Pulm Dis       Date:  2019-11

8.  COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.

Authors:  Katherine E Lowe; Elizabeth A Regan; Antonio Anzueto; Erin Austin; John H M Austin; Terri H Beaty; Panayiotis V Benos; Christopher J Benway; Surya P Bhatt; Eugene R Bleecker; Sandeep Bodduluri; Jessica Bon; Aladin M Boriek; Adel Re Boueiz; Russell P Bowler; Matthew Budoff; Richard Casaburi; Peter J Castaldi; Jean-Paul Charbonnier; Michael H Cho; Alejandro Comellas; Douglas Conrad; Corinne Costa Davis; Gerard J Criner; Douglas Curran-Everett; Jeffrey L Curtis; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Jennifer G Dy; Ashraf Fawzy; Margaret Fleming; Eric L Flenaugh; Marilyn G Foreman; Spyridon Fortis; Hirut Gebrekristos; Sarah Grant; Philippe A Grenier; Tian Gu; Abhya Gupta; MeiLan K Han; Nicola A Hanania; Nadia N Hansel; Lystra P Hayden; Craig P Hersh; Brian D Hobbs; Eric A Hoffman; James C Hogg; John E Hokanson; Karin F Hoth; Albert Hsiao; Stephen Humphries; Kathleen Jacobs; Francine L Jacobson; Ella A Kazerooni; Victor Kim; Woo Jin Kim; Gregory L Kinney; Harald Koegler; Sharon M Lutz; David A Lynch; Neil R MacIntye; Barry J Make; Nathaniel Marchetti; Fernando J Martinez; Diego J Maselli; Anne M Mathews; Meredith C McCormack; Merry-Lynn N McDonald; Charlene E McEvoy; Matthew Moll; Sarah S Molye; Susan Murray; Hrudaya Nath; John D Newell; Mariaelena Occhipinti; Matteo Paoletti; Trisha Parekh; Massimo Pistolesi; Katherine A Pratte; Nirupama Putcha; Margaret Ragland; Joseph M Reinhardt; Stephen I Rennard; Richard A Rosiello; James C Ross; Harry B Rossiter; Ingo Ruczinski; Raul San Jose Estepar; Frank C Sciurba; Jessica C Sieren; Harjinder Singh; Xavier Soler; Robert M Steiner; Matthew J Strand; William W Stringer; Ruth Tal-Singer; Byron Thomashow; Gonzalo Vegas Sánchez-Ferrero; John W Walsh; Emily S Wan; George R Washko; J Michael Wells; Chris H Wendt; Gloria Westney; Ava Wilson; Robert A Wise; Andrew Yen; Kendra Young; Jeong Yun; Edwin K Silverman; James D Crapo
Journal:  Chronic Obstr Pulm Dis       Date:  2019-11

9.  Co-Morbidity Patterns Identified Using Latent Class Analysis of Medications Predict All-Cause Mortality Independent of Other Known Risk Factors: The COPDGene® Study.

Authors:  Yisha Li; Margaret Ragland; Erin Austin; Kendra Young; Katherine Pratte; John E Hokanson; Terri H Beaty; Elizabeth A Regan; Stephen I Rennard; Christina Wern; Michael R Jacobs; Ruth Tal-Singer; Barry J Make; Gregory L Kinney
Journal:  Clin Epidemiol       Date:  2020-10-27       Impact factor: 4.790

10.  Diagnosing and treating lung disease at the cellular level.

Authors:  Lisa Postow; Patricia Noel; Sara Lin; Guofei Zhou; Josh Fessel; James P Kiley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.